Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Profit After Tax (2016 - 2025)

Amphastar Pharmaceuticals has reported Profit After Tax over the past 13 years, most recently at $24.4 million for Q4 2025.

  • Quarterly results put Profit After Tax at $24.4 million for Q4 2025, down 35.65% from a year ago — trailing twelve months through Dec 2025 was $98.1 million (down 38.51% YoY), and the annual figure for FY2025 was $98.1 million, down 38.51%.
  • Profit After Tax for Q4 2025 was $24.4 million at Amphastar Pharmaceuticals, up from $17.3 million in the prior quarter.
  • Over the last five years, Profit After Tax for AMPH hit a ceiling of $49.2 million in Q3 2023 and a floor of $5.0 million in Q1 2021.
  • Median Profit After Tax over the past 5 years was $26.1 million (2023), compared with a mean of $27.4 million.
  • Biggest five-year swings in Profit After Tax: skyrocketed 4145.31% in 2021 and later plummeted 57.09% in 2025.
  • Amphastar Pharmaceuticals' Profit After Tax stood at $19.8 million in 2021, then soared by 71.62% to $33.9 million in 2022, then rose by 6.65% to $36.2 million in 2023, then grew by 4.97% to $38.0 million in 2024, then crashed by 35.65% to $24.4 million in 2025.
  • The last three reported values for Profit After Tax were $24.4 million (Q4 2025), $17.3 million (Q3 2025), and $31.0 million (Q2 2025) per Business Quant data.